Skip to main content
High-dose methotrexate does not reduce CNS progression risk in high-risk aggressive BCL
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
High-dose methotrexate does not reduce CNS progression risk in high-risk aggressive BCL
User login
Username
Password
Reset your password
Concept
Lead
score
Chronic Lymphocytic Leukemia
1
1
Antineoplastic Drug
0
1
Biologic Therapy
0
1
Monoclonal Antibody
0
0.95
Leukemia
0
0.27
Cancer
0
0.11
Specialty
Lead
score
Hematology-Oncology
1
1
Pharmacist
0
1
Edit Tags